Noxopharm attracts $4 million for three drugs targeting unmet medical needs
Each of these three drugs is currently in pre-clinical development.
Company
Noxopharm Ltd
ASX:NOX
Noxopharm Limited is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines. The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).
93 stories · page 5 of 5
Noxopharm calls for halt pending clarification of intellectual property
The halt will remain in place until Monday 27th November 2017.
Noxopharm to reveal clinical trial data
The halt will remain in place until Tuesday 21st November 2017.
Noxopharm identifies drug candidate to reduce the impact of human stroke
The company has collaborated with the University of New South Wales.
Noxopharm commences late stage prostate cancer clinical trial
The company has initiated the Phase 1b study involving 24 men.
Noxopharm making steady progress on its anti-cancer drug program
Latest findings signals the potential use of NOX66 in treating malignant brain cancer.
Noxopharm pockets $5.5M to accelerate cancer drug development
NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil.
Noxopharm calls for halt in shares
The halt will remain in place until Wednesday 23rd August 2017.
Noxopharm shares ride higher on initiating anti-cancer trials
NOX66 is as a drug that makes existing therapies work more effectively.
Noxopharm to commence first clinical trial of promising anti-cancer drug
The first-in-human study will involve patients with late-stage cancer.
Noxopharm to begin clinical study of cancer drug in Georgia
Noxopharm Ltd (ASX:NOX) is scheduled to begin its inaugural clinical study of experimental anti-cancer product, NOX66, in December 2016.